Angiogenesis is an important feature of cancer cells, and although available in vitro data have demonstrated that olverembatinib potently inhibits VEGFRs, a lack of suitable SDH-deficient GIST animal models is a significant hurdle preventing potential evaluation of the antiangiogenic effects of the compound. The gene discussed is SDHB; the disease is cancer.